bpc-157 diverticulitis Explained: Benefits, Safety & Oral vs Injectable Options BPC RAPID - 250MCG |

Principal Research Scientist Dr Md Masum Mia from Duke-NUS' Cardiovascular and Metabolic Disorders Programme, the study's first author, said of the findings: "This breakthrough not only deepens our understanding of the specific molecular mechanisms responsible for pulmonary fibrosis, but could also lead to treatments that halt or even reverse lung scarring in the disease." Paving the way for new treatment options for pulmonary fibrosis Global early-phase clinical trials for novel therapies that target YAP and TAZ in cancers, which are characterised by immune-driven inflammation and scarring, are underway, and the research team is exploring if such therapies are viable for treating patients with pulmonary fibrosis

Pain 1977;4:16174.ArticlePubMed 8

and C.-T.H

Maryke Louw 5 min read bottom of page